News Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
106.7 ^USD	-1.51%		-0.46%	+15.68%

May. 06	Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing	MT
May. 06	Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing	May. 06	MT
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 06	PR
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating	May. 06	MT
Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97	May. 06	MT
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT Full Year Revenue Guidance	May. 03	AQ
Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating	May. 02	MT
Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises	May. 02	MT
Transcript : Blueprint Medicines Corporation, Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M	May. 02	MT
Blueprint Medicines: Q1 Earnings Snapshot	May. 02	AQ
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024	May. 02	CI
Transcript : Blueprint Medicines Corporation - Special Call	Apr. 25
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024	Apr. 18	PR
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics	Apr. 11	PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 04	PR
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	Mar. 22	MT
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 06	PR
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	Mar. 01	MT
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	Feb. 26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Summary

Filters